📊 NVACW Key Takeaways
Is NVACW a Good Investment? Thesis Analysis
Profusa is a pre-revenue or near-zero revenue medical device company with severe financial distress characterized by massive operating losses (-$24.1M), negative stockholders' equity (-$34.0M), and critical cash burn (-$11.1M operating cash flow). The company's liabilities ($38.2M) far exceed assets ($4.2M), and liquidity metrics indicate imminent solvency concerns with a current ratio of 0.18x.
Why Buy NVACW? Key Strengths
- Operating in high-growth medical devices sector (surgical instruments)
- 9 Form 4 insider filings suggest ongoing corporate activity
- Retained $3.0M in cash and equivalents as of latest period
NVACW Investment Risks to Consider
- Negative stockholders' equity of -$34.0M indicates balance sheet insolvency
- Critical liquidity crisis with current ratio of 0.18x and liabilities exceeding assets by $34.0M
- Unsustainable cash burn of -$11.1M annually with minimal revenue generation ($100K) cannot support operations
- Operating margin of -24,136% demonstrates complete operational failure to generate revenue relative to expenses
Key Metrics to Watch
- Path to revenue generation and product commercialization timeline
- Monthly cash burn rate and runway until capital depletion
- Balance sheet restructuring or capital raise announcements to address negative equity
NVACW Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
NVACW Profitability Ratios
NVACW vs Healthcare Sector
How Profusa, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NVACW Overvalued or Undervalued?
Based on fundamental analysis, Profusa, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NVACW Balance Sheet & Liquidity
NVACW 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Profusa, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $0.12 reflects profitable operations.
NVACW Growth Metrics (YoY)
NVACW Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $75.0K | -$2.1M | $-0.70 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NVACW Capital Allocation
NVACW SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Profusa, Inc. (CIK: 0001859807)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NVACW
What is the AI rating for NVACW?
Profusa, Inc. (NVACW) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NVACW's key strengths?
Claude: Operating in high-growth medical devices sector (surgical instruments). 9 Form 4 insider filings suggest ongoing corporate activity.
What are the risks of investing in NVACW?
Claude: Negative stockholders' equity of -$34.0M indicates balance sheet insolvency. Critical liquidity crisis with current ratio of 0.18x and liabilities exceeding assets by $34.0M.
What is NVACW's revenue and growth?
Profusa, Inc. reported revenue of $100.0K.
Does NVACW pay dividends?
Profusa, Inc. does not currently pay dividends.
Where can I find NVACW SEC filings?
Official SEC filings for Profusa, Inc. (CIK: 0001859807) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NVACW's EPS?
Profusa, Inc. has a diluted EPS of $-2.29.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NVACW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Profusa, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NVACW stock overvalued or undervalued?
Valuation metrics for NVACW: ROE of N/A (sector avg: 15%), net margin of -27,256.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NVACW stock in 2026?
Our dual AI analysis gives Profusa, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NVACW's free cash flow?
Profusa, Inc.'s operating cash flow is $-11.1M, with capital expenditures of N/A. FCF margin is -11,119.0%.
How does NVACW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -27,256.0% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.18 (avg: 2).